17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof

A compound represented by one of Formulas (X-2), (X-3), (X-4), (X-5), (X-6), (X-11) and (X-12), or a pharmaceutically acceptable salt thereof:

• wherein each R11 is independently selected from the group consisting of halogen, hydroxy, —NH2, —NHMe, —NMe2, —CN, —NO2, optionally substituted-C1-C6 alkyl, optionally substituted-C1-C6 alkoxyl, optionally substituted-C3-C6 cycloalkyl, optionally substituted-C3-C6 cycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl;
• n is 0, 1, 2, or 3;
• each R12 is independently selected from the group consisting of halogen, hydroxy, —NH2, —NHMe, —NMe2, —CN, —NO2, optionally substituted-C1-C6 alkyl, optionally substituted-C1-C6 alkoxyl, optionally substituted-C3-C6 cycloalkyl, optionally substituted-C3-C6 cycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl;
• m is 0, 1 or 2;
• R13 is selected from the group consisting of hydrogen, halogen, hydroxy, —NH2, —NHMe, —NMe2, —CN, —NO2, optionally substituted-C1-C6 alkyl, optionally substituted-C1-C6 alkoxyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C3-C6 cycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl;
• is optionally substituted aryl;
• and
• is optionally substituted-C3-C12 cycloalkyl, optionally substituted 3- to 12-membered heterocycloalkyl, or optionally substituted-C3-C12 cycloalkenyl.